N-Cyclohexylethanesulfinamide | 62659-46-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 亚磺酸及其衍生物
• 英文名称: N-Cyclohexylethanesulfinamide
• 英文别名: N-cyclohexylethanesulfinamide
• CAS: 62659-46-5
• 化学式: C₈H₁₇NOS
• 分子量: 175.29
• InChiKey: YFNFYGDZUVHIJF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  48.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：EP2017261A1

  公开（公告）日：2009-01-21

  This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is optionally substituted lower alkyl, Y is -S(O)n- wherein n is 1 or 2, or -CO-, R2 is hydrogen or lower alkyl, R7 is hydrogen or lower alkyl, X is lower alkylene, lower alkenylene, arylene, cycloalkylene or the like, and Z is lower alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl or the like.

  本发明提供了一种式 (I) 的化合物： 其药学上可接受的盐或溶液、 其中 R1 是任选取代的低级烷基、 Y是-S(O)n- 其中n是1或2，或-CO-、 R2 是氢或低级烷基 R7 是氢或低级烷基 X 是低级烯烃、低级烯烃、芳烃、环烷烃或类似物，以及 Z 是低级烷基、任选取代的碳环烷基、任选取代的杂环烷基或类似物。
• 5-MEMBERED RING AROMATIC HETEROCYCLIC DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2703392B1

  公开（公告）日：2017-06-14
• TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF
  申请人：Seldar Pharma Inc.

  公开号：US20190000832A1

  公开（公告）日：2019-01-03

  To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.